 |
54 Diseases |  |
8 Trials |
|
8 Trials |  |
2662 News |  |
| «12...12131415161718192021222324» |
- ||||| ledipasvir/sofosbuvir / Generic mfg.
New P4 trial: Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia (clinicaltrials.gov) - Jan 15, 2015
P4, N=1000, Enrolling by invitation, Sponsor: National Institutes of Health Clinical Center (CC)
- |||| ledipasvir/sofosbuvir / Generic mfg.
Trial primary completion date: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection (clinicaltrials.gov) - Dec 24, 2014
P3, N=300, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Mar 2015 --> Nov 2015
- ||| voxilaprevir (GS-9857) / Gilead
Enrollment change: LEPTON: Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection (clinicaltrials.gov) - Dec 24, 2014
P2, N=330, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Mar 2015 --> Nov 2015 N=125 --> 330
- | ledipasvir/sofosbuvir / Generic mfg.
New P2 trial: HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus Infection (clinicaltrials.gov) - Dec 5, 2014
P2, N=20, Recruiting, Sponsor: HepNet Study House, German Liverfoundation
- | ledipasvir/sofosbuvir / Generic mfg.
New P2 trial: Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease (clinicaltrials.gov) - Nov 28, 2014
P2, N=25, Not yet recruiting, Sponsor: Gilead Sciences
- |||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial completion: Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination (clinicaltrials.gov) - Nov 20, 2014
P2, N=155, Completed, Sponsor: Gilead Sciences
N=125 --> 330 Active, not recruiting --> Completed
- |||| ledipasvir/sofosbuvir / Generic mfg.
Enrollment open: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection (clinicaltrials.gov) - Nov 18, 2014
P2, N=200, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Sovaldi (sofosbuvir) / Gilead
Clinical: A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection (clinicaltrials.gov) - Nov 17, 2014
P=N/A, N=1300, Enrolling by invitation, Sponsor: Gilead Sciences
- ||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders (clinicaltrials.gov) - Nov 17, 2014
P2, N=125, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| ledipasvir/sofosbuvir / Generic mfg.
Enrollment open: Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection (clinicaltrials.gov) - Nov 7, 2014
P2, N=150, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial completion, Trial primary completion date: Efficacy and Safety of Sofosbuvir/Ledipasvir (clinicaltrials.gov) - Oct 15, 2014
P3, N=341, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Jun 2014
- | vedroprevir (GS 9451) / Gilead
Enrollment closed: Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis (clinicaltrials.gov) - Oct 10, 2014
P2, N=50, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Jun 2014 Recruiting --> Active, not recruiting
- ||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed, Metastases: Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant (clinicaltrials.gov) - Sep 30, 2014
P2, N=400, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| ledipasvir/sofosbuvir / Generic mfg.
New P2 trial: Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection (clinicaltrials.gov) - Sep 29, 2014
P2, N=150, Not yet recruiting, Sponsor: Gilead Sciences
- || ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial primary completion date: Ledipasvir/Sofosbuvir Fixed-Dose Combination (clinicaltrials.gov) - Sep 28, 2014
P2, N=100, Enrolling by invitation, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2015 --> Oct 2015
- ||||| ledipasvir/sofosbuvir / Generic mfg.
New P2 trial: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection (clinicaltrials.gov) - Sep 28, 2014
P2, N=200, Not yet recruiting, Sponsor: Gilead Sciences
- ||||| ledipasvir/sofosbuvir / Generic mfg.
Enrollment change, Trial primary completion date: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection (clinicaltrials.gov) - Sep 5, 2014
P3, N=360, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Mar 2015 --> Oct 2015 N=160 --> 360 | Trial primary completion date: Sep 2014 --> Mar 2017
- | ledipasvir/sofosbuvir / Generic mfg.
Enrollment open: Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection (clinicaltrials.gov) - Sep 5, 2014
P2, N=40, Recruiting, Sponsor: Gilead Sciences
N=160 --> 360 | Trial primary completion date: Sep 2014 --> Mar 2017 Not yet recruiting --> Recruiting
- | vedroprevir (GS 9451) / Gilead
New P2 trial: Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis (clinicaltrials.gov) - Aug 27, 2014
P2, N=50, Recruiting, Sponsor: Gilead Sciences
- ledipasvir/sofosbuvir / Generic mfg.
Trial completion, Enrollment change: Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection (clinicaltrials.gov) - Aug 22, 2014
P2, N=5, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=35 --> 5
- | ledipasvir/sofosbuvir / Generic mfg.
New P2 trial: Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection (clinicaltrials.gov) - Aug 19, 2014
P2, N=40, Not yet recruiting, Sponsor: Gilead Sciences
- |||| voxilaprevir (GS-9857) / Gilead
Enrollment open: LEPTON: Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection (clinicaltrials.gov) - Aug 15, 2014
P2, N=125, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed | N=35 --> 5 Not yet recruiting --> Recruiting
- ||| radalbuvir (GS-9669) / Gilead
Enrollment closed, Trial initiation date: Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection (clinicaltrials.gov) - Aug 15, 2014
P2, N=410, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Initiation date: Aug 2013 --> Apr 2013
- |||| radalbuvir (GS-9669) / Gilead
Trial completion: Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection (clinicaltrials.gov) - Aug 4, 2014
P2, N=101, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting | Initiation date: Aug 2013 --> Apr 2013 Active, not recruiting --> Completed
- ledipasvir/sofosbuvir / Generic mfg.
Trial initiation date: Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection (clinicaltrials.gov) - Aug 1, 2014
P2, N=70, Not yet recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Active, not recruiting --> Completed Initiation date: Apr 2014 --> Sep 2014
- ||||| voxilaprevir (GS-9857) / Gilead
New P2 trial: LEPTON: Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection (clinicaltrials.gov) - Jul 30, 2014
P2, N=125, Not yet recruiting, Sponsor: Gilead Sciences
- ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Enrollment open: SWIFT-C: Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection (clinicaltrials.gov) - Jul 30, 2014
P1, N=44, Recruiting, Sponsor: AIDS Clinical Trials Group
Initiation date: Apr 2014 --> Sep 2014 Not yet recruiting --> Recruiting
- ||| ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection (clinicaltrials.gov) - Jun 18, 2014
P2, N=80, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection (clinicaltrials.gov) - Jun 13, 2014
P3, N=300, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed, Metastases: Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant (clinicaltrials.gov) - May 14, 2014
P2, N=400, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial primary completion date: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV (clinicaltrials.gov) - May 11, 2014
P3, N=870, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2014 --> Feb 2014
- ||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial completion date: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV (clinicaltrials.gov) - May 11, 2014
P3, N=870, Completed, Sponsor: Gilead Sciences
Trial primary completion date: Oct 2014 --> Feb 2014 Trial completion date: Dec 2014 --> Apr 2014
- ||||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial completion: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV (clinicaltrials.gov) - May 11, 2014
P3, N=870, Completed, Sponsor: Gilead Sciences
Trial completion date: Dec 2014 --> Apr 2014 Active, not recruiting --> Completed
- ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P1 trial: SWIFT-C: Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection (clinicaltrials.gov) - Apr 28, 2014
P1, N=44, Not yet recruiting, Sponsor: AIDS Clinical Trials Group
- | ledipasvir/sofosbuvir / Generic mfg.
New P2 trial: Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection (clinicaltrials.gov) - Apr 23, 2014
P2, N=70, Not yet recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
- ||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P2 trial: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders (clinicaltrials.gov) - Apr 20, 2014
P2, N=125, Recruiting, Sponsor: Gilead Sciences
- ||| ledipasvir/sofosbuvir / Generic mfg.
Trial initiation date: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection (clinicaltrials.gov) - Apr 13, 2014
P2, N=80, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Initiation date: Mar 2014 --> Apr 2014
- |||| ledipasvir/sofosbuvir / Generic mfg.
Enrollment open: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection (clinicaltrials.gov) - Apr 13, 2014
P2, N=80, Recruiting, Sponsor: Gilead Sciences
Initiation date: Mar 2014 --> Apr 2014 Not yet recruiting --> Recruiting
- ||||| ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection (clinicaltrials.gov) - Mar 9, 2014
P3, N=160, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial completion: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (clinicaltrials.gov) - Mar 9, 2014
P3, N=647, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| ledipasvir/sofosbuvir / Generic mfg.
New P2 trial: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection (clinicaltrials.gov) - Mar 5, 2014
P2, N=80, Recruiting, Sponsor: Gilead Sciences
- |||||| ledipasvir/sofosbuvir / Generic mfg.
Enrollment open: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection (clinicaltrials.gov) - Feb 27, 2014
P3, N=300, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial completion: ION-2: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (clinicaltrials.gov) - Feb 26, 2014
P3, N=441, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| ledipasvir/sofosbuvir / Generic mfg.
New P3 trial: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection (clinicaltrials.gov) - Feb 25, 2014
P3, N=300, Recruiting, Sponsor: Gilead Sciences
- ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Enrollment open, Metastases: Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant (clinicaltrials.gov) - Feb 10, 2014
P2, N=400, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| radalbuvir (GS-9669) / Gilead
Enrollment closed: Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection (clinicaltrials.gov) - Feb 3, 2014
P2, N=90, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial completion: Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) (clinicaltrials.gov) - Jan 20, 2014
P2, N=100, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| radalbuvir (GS-9669) / Gilead
Trial completion: Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Na (clinicaltrials.gov) - Jan 20, 2014
P2, N=292, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| ledipasvir/sofosbuvir / Generic mfg.
New P3 trial: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection (clinicaltrials.gov) - Dec 25, 2013
P3, N=160, Active, not recruiting, Sponsor: Gilead Sciences
- ||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination (clinicaltrials.gov) - Dec 23, 2013
P2, N=150, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting